Company
Nanopath
Diagnostics for Women.
- Status
- Operatingas of 2026-09-20
- Business model
- B2B
- nanopathdx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Nanopath is commercializing a first-in-class molecular diagnostic platform to enable scalable, point-of-care disease diagnosis.
Funding snapshot
- Total raised
- $15.3MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Grant, $3M2024-05
Funding rounds
- Round, 2025
- $5.3M2025-01-24, SEC form D sold, 5 investors
- Grant
- $3M2024-05, Company stated
- Series A
- $10M2022-08, Company stated
- Round, 2022
- $10M2022-06-14, SEC form D sold, 10 investors
Products
- Other
- molecular diagnostic platform
Loading relationship preview